Vir Biotechnology | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Vir Biotechnology
- Entry Bias Hypothesis 1 | Center Settings
- Entry Bias Hypothesis 2 | Supply Area
- 12345 | Wave 1 | Failed Target
- Retracement | 0618 & 0.5 Area | Infliction
-
VIR - long - catalyst / gap playVir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic
VIR -Analysts expect much more, but for now let's settle for~$22Still in a dangerous zone but breaking a resistance level after shuffling with supporting volume and oscillators returning to positive territory
Buy - $11.3
First target - $14.45
Second target - around $22
If the stock reaches these numbers we will talk about additional goals, right now it's too ear
WATCH $VIRBullish
Fundamental
- High inflationary Macro environment / no fear sentiment
- Funds Accumulation
- Positive PE
- Positive PEG
- Positive P/FCF
- Top Sector / Industry
- Moderate floats
- High short interest / 7 days + 58%
- Impressive sales ?
Technical
- - Momentum Theory Indicator - N
VIR : hold on and be patient After the very good results of the first quarter,the stock reacted well. The hepatitis cases remain under control. The company's balance sheet is clean and this gives hope for the future...
VIR - the fundamental playThere is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!
And market prices them like @#$! while they will earn around their own 1x marke
VIR Double Falling WedgeAnalysis for VIR
Two falling wedges can be seen to have formed in this current down move
As in the previous down move, price temporarily moves out of the channel before moving back up
This is what's occurring now with this second falling wedge
I do expect a big break out at this huge support area
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmit
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.